The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch.
Brazil’s patent law does not allow methods of treatment to be patented, but there are other means of getting protection, according to Kene Gallois and Samantha Salim of Daniel Law.
It is challenging but not impossible to protect software innovations in Mexico, according to Alejandro Moreno Hernández of Uhthoff, Gomez Vega & Uhthoff.
ACI’s 17th Global Summit on Life Sciences Patents returns to New York on May 15-17, 2019, to provide practical insights on how to maximise your patent term and develop strategies to enhance protections for your patent portfolio.
The political influence on patent rights during Brazil’s general election in October has set a worrying precedent, writes Gabriel Di Blasi of Di Blasi Parente & Associados.
Hector Chagoya and Mariana Gonzalez-Vargas of Becerril, Coca & Becerril examine how Mexico applies the Budapest Treaty, which covers microorganisms in the patent process.
A new facet of Mexico’s linkage system between patents and pharmaceutical drugs raises several questions that necessitate a careful approach from patent assignees and agents, as Mariana Gonzalez-Vargas of Becerril, Coca & Becerril reports.
With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected.
While cannabis companies in the US can’t protect their brands with federal trademark protection, there are other options for them when seeking IP rights, as LSIPR finds out.
The implementation of precision medicine represents a huge, possibly unprecedented, challenge to conventional clinical practice across the breadth of healthcare disciplines, says Daniel Lim of Kirkland & Ellis.